Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;65(5):629-632.
doi: 10.1111/aas.13757. Epub 2020 Dec 20.

Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile?

Christopher Lotz  1 , Ralf M Muellenbach  2 , Patrick Meybohm  1 , Haitham Mutlak  3 , Philipp M Lepper  4 , Caroline-Barbara Rolfes  2 , Asghar Peivandi  5 , Jan Stumpner  1 , Markus Kredel  1 , Peter Kranke  1 , Iuliu Torje  2 , Christian Reyher  2
Affiliations

Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile?

Christopher Lotz et al. Acta Anaesthesiol Scand. 2021 May.

Abstract

Background: Changes in pulmonary hemodynamics and ventilation/perfusion were proposed as hallmarks of Coronavirus disease 2019 (COVID-19)-induced acute respiratory distress syndrome (ARDS). Inhaled nitric oxide (iNO) may overcome these issues and improve arterial oxygenation.

Methods: We retrospectively analyzed arterial oxygenation and pulmonary vasoreactivity in seven COVID-19 ARDS patients receiving 20 ppm iNO for 15-30 minutes.

Results: The inhalation of NO significantly improved oxygenation. All patients with severe ARDS had higher partial pressures of oxygen and reduced pulmonary vascular resistance. Significant changes in pulmonary shunting were not observed.

Conclusion: Overall, iNO could provide immediate help and delay respiratory deterioration in COVID-19-induced moderate to severe ARDS.

Keywords: ARDS; COVID-19; nitric oxide; vasoreactivity.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099-1102.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
    1. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328(6):399-405.
    1. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;2016:CD002787.
    1. World Health Organization. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance. World Health Organization. March 19, 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-nove.... Accessed April 29, 2020.

MeSH terms

LinkOut - more resources